The marijuana industry is super busy with deal activities. A number of alcoholic beverage companies are investing or partnering with cannabis producers in a move to benefit from Canada's move to legalize marijuana for recreational use. The latest catalyst is the marlboro cigarette maker Altria Group (
MO - Free Report) , which announced that it will invest $1.8 billion (C$2.4 billion) in Canadian cannabis producer Cronos Group ( CRON - Free Report) . As part of the deal, Altria will buy 146.2 million Cronos shares at C$16.25 a piece, which marks a 16.2% premium to the Dec 6 close on the Toronto Stock Exchange and a 41.5% premium to the company's 10-day volume weighted average price ending Nov 30. The investment will represent a 45% equity stake in Cronos with a warrant to increase ownership to 55% over the next four years. The transaction is expected to finalize within the first half of 2019. Shares of CRON rallied 21.7% at the close on Dec 7 (read: Another Cannabis ETF on the Way). The news sparked a rally in the broad cannabis sector and raised hopes of further investments. Corona beer maker Constellation Brands ( STZ - Free Report) in August announced a $4 billion investment in Canadian cannabis producer Canopy Growth ( CGC - Free Report) , marking the biggest investment in the industry. VIDEO
In other news, Aurora Cannabis (
ACB - Free Report) jumped 10.8% after it announced its expansion into Mexico with the establishment of an exclusive supply deal with Farmacias Magistrales S.A. The company said Farmacias, a pharmaceutical manufacturer and distributor that reaches 80,000 retail points and 500 pharmacies and hospitals, recently received the first import license graded from the Mexico's Federal Commission for Protection Against Health Risks, which allows the company to import medical cannabis containing THC. Leafbuyer Technologies recently partnered with recreational and medical cannabis dispensaries throughout several legal markets to bring consumers the best deals for the 2018 Green Friday Deals Event in late November. As such, ETFMG Alternative Harvest ETF (— the first and only pure ETF targeting the cannabis/marijuana industry — surged nearly 5% on the news. The fund has been on a tough ride this quarter on a profit taking and weak earnings after an astounding surge in the third quarter. From a year-to-date basis, the ETF is down 10.8% (read: MJ - Free Report) Top and Flop ETFs at Half-Way Q4). MJ in Focus The fund tracks the Prime Alternative Harvest Index designed to measure the performance of companies within the cannabis ecosystem, benefiting from global medicinal and recreational cannabis legalization initiatives. The fund holds 38 securities in its basket and Canadian firms make up for half of the portfolio, while American firms comprise 36%. The ETF has AUM of $622.5 million and trades in a good volume of around 710,000 shares. It charges 75 bps in annual fees. What Lies Ahead? The pot industry has been emerging and is poised for rapid growth given its widespread legality. Though cannabis remains illegal at the federal level in the United States, nine states and the District of Columbia have legalized recreational marijuana while 30 states have legalized medical weed. Canada is now the second country in the world to legalize the drug for both medical and recreational use, trailing Uruguay and the first country among the G-7 nations (read: Will Cannabis ETFs be on a High Again?). According to the Arcview Market Research, the U.S. legal cannabis market is projected to reach $11 billion in consumer spending this year and more than $23 billion by 2022. Per an analyst at Cowen, the U.S. legal cannabis industry is expected to reach $75 billion in sales by 2030, surpassing the carbonated soft drink market in 2017.
Want key ETF info delivered straight to your inbox? Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>